Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease
TA Lee, AS Pickard, DH Au, B Bartle… - Annals of internal …, 2008 - acpjournals.org
Background: Concerns exist regarding increased risk for mortality associated with some
chronic obstructive pulmonary disease (COPD) medications. Objective: To examine the …
chronic obstructive pulmonary disease (COPD) medications. Objective: To examine the …
Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients
JB Soriano, VA Kiri, NB Pride, J Vestbo - American Journal of Respiratory …, 2003 - Springer
Introduction: In patients with COPD who have recently been hospitalized for their disease,
we examined whether treatment with inhaled corticosteroids without or with long-acting β …
we examined whether treatment with inhaled corticosteroids without or with long-acting β …
Cardiovascular disease and COPD: dangerous liaisons?
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD)
frequently occur together and their coexistence is associated with worse outcomes than …
frequently occur together and their coexistence is associated with worse outcomes than …
Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis
J Wang, B Nie, W Xiong, Y Xu - Journal of clinical pharmacy …, 2012 - Wiley Online Library
Summary What is Known and Objective: Inhaled long‐acting beta‐agonists have been
licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late …
licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late …
Beta-blockers in COPD: time for reappraisal
The combined effects on the heart of smoking and hypoxaemia may contribute to an
increased cardiovascular burden in chronic obstructive pulmonary disease (COPD). The use …
increased cardiovascular burden in chronic obstructive pulmonary disease (COPD). The use …
[HTML][HTML] Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study
Introduction Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ ICS)
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis
Background: Most patients with moderate and severe chronic obstructive pulmonary disease
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …
[HTML][HTML] Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
Background Most patients with chronic obstructive pulmonary disease (COPD) receive
inhaled long-acting bronchodilators and inhaled corticosteroids. Conventional meta …
inhaled long-acting bronchodilators and inhaled corticosteroids. Conventional meta …
β-Blockers are associated with a reduction in COPD exacerbations
Background While some retrospective studies have suggested that β-blocker use in patients
with COPD is associated with a reduction in the frequency of acute exacerbations and lower …
with COPD is associated with a reduction in the frequency of acute exacerbations and lower …
[HTML][HTML] Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability
VS Fan, I Gylys-Colwell, E Locke, K Sumino… - Respiratory …, 2016 - Elsevier
Background Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is
known about overuse of SABA in chronic obstructive pulmonary disease (COPD). Methods …
known about overuse of SABA in chronic obstructive pulmonary disease (COPD). Methods …